SAN DIEGO, CA / ACCESSWIRE / March 21, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending in Indiana for certain purchasers of shares of Supreme Industries, Inc. (NYSE MKT: STS) over alleged Securities Laws Violations by Supreme Industries, Inc.

Investors who purchased shares of Supreme Industries, Inc. (NYSE MKT: STS) in June 2016 or earlier and currently hold any of those NYSE MKT: STS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The lawsuit was originally filed in November 2016, and is currently pending against Supreme Industries, Inc. The plaintiff alleged that the defendants were in violation of the Securities Exchange Act of 1934. More specifically, the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the backlog figure from the third quarter of 2015 was a result of the timing of several large orders placed in that quarter, that the backlog figure for the third quarter of 2016 would not be close to the backlog figure of the third quarter of 2015, and that as a result, defendants’ public statements about Supreme Industries’ business, operations and prospects were materially false and misleading at all relevant times.

According to the complaint, following an October 21, 2016 press release, conference call, and report announcing that the lower backlog comparison is due to two large fleet replacement orders and the timing of an annual fleet account order received during the third quarter of last year and that the circumstances surrounding the backlog of the third quarter of 2015 was unique, the value of Supreme Industries, Inc. (NYSE MKT: STS) shares declined significantly.

On February 14, 2017, the case was transferred from the U.S. District Court for the Central District of California to the U.S. District Court for the Norther District of Indiana.

Those who purchased Supreme Industries, Inc. (NYSE MKT: STS) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 457806

SAN DIEGO, CA / ACCESSWIRE / March 21, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending in New York for certain purchasers of shares of General Cable Corporation (NYSE: BGC) over alleged Securities Laws Violations by General Cable.

Investors, who purchased shares of General Cable Corporation in January 2012 or earlier and currently hold any of those NYSE: BGC shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The lawsuit was originally filed in January 2017 and is currently pending against General Cable Corporation. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that General Cable paid millions of dollars in bribes to government officials in foreign countries, including Angola, Bangladesh, China, Egypt, Indonesia, India, and Thailand, in order to secure business, that the foregoing conduct was in violation of the FCPA, that General Cable’s revenues were therefore in part the product of illegal conduct, and, as such, subject to disgorgement and unlikely to be sustainable, that the foregoing conduct, when it became known, would subject the Company to significant regulatory scrutiny and financial penalties, and that as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.

Those who purchased General Cable (NYSE: BGC) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 457807

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / Microvision and Pixelworks are two companies that both focus on the mobile display markets, a key sector in the consumer and electronics markets. The demand for small form technologies continues to grow, and as Apple and other tablet companies have started to see their demand flatten, the hunt is on for ways to increase consumer interest. As with virtually all technologies, they are either made competitive by new features or by lowering prices to attract new buyers.

RDI Initiates
Coverage:

Microvision, Inc. https://ub.rdinvesting.com/news/?ticker=MVIS

Pixelworks, Inc. https://ub.rdinvesting.com/news/?ticker=PXLW

The company saw its stock rise 52 cents a share to close at $2.60 on Monday. Microvision is an innovator in miniature display technology, and announced on Wednesday, March 15, it had received its first order for its small form factor display engine and from 16th March, within three days the stock price shoot up nearly 42 percent. The order came from an unnamed Asian electronics device manufacturer with a total contract of $6.7 million. Currently, the units are expected to begin shipment during the 2nd quarter of this year. The vast majority of units will be shipped by the end of the year. This initial shipment is a primer to determine the future of the demand for Asian electronics in the east. Depending on the outcomes, the current price of $2.60 a share may be a bargain by the end of 2017, as this $6.7 million of sales order is over 45 percent of its revenue of $14.8 million reported for the year 2016. Microvision has reported loss of $16.5 million or $0.32 a share on revenue of $14.8 million for the year 2016 and it had $15.1 million of reported cash and cash equivalents as on December 31
st, 2016.

Access RDI’s Microvision Research Report at: https://ub.rdinvesting.com/news/?ticker=MVIS

The company closed down from the trading day’s opening high of $4.84 per share. The 21 cent decline occurred with no visible news as to why. Pixelworks is a company that designs and markets display technologies for mobile phone and device manufacturers. Although there are very few research firms that cover this company, it has its investment ratings as “buy” given by most of the analysts covering this company, according to Wall Street Journal. Lake Street has lifted ratings of the company in February from “hold” to “buy” post it’s fourth quarter and full year 2016 result, the company recently also has caught the attention of Zacks investment rating service. Pixelworks has reported net loss of $11.1 million or $0.39 a share on revenue of $53.4 million for the year 2016 as compared to net loss of $10.6 million or $0.42 share on revenue of $59.5 million reported in the year 2015.

Access RDI’s Pixelworks Research Report at: https://ub.rdinvesting.com/news/?ticker=PXLW

Our Actionable Research on Microvision, Inc. (NASDAQ: MVIS) and Pixelworks, Inc. (NASDAQ: PXLW) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457817

VICTORIA, BC / ACCESSWIRE / March 21, 2017 / FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE MKT: FSI, FRANKFURT: FXT), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients, and water treatment, as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today, the Company announces the results from a California WaterSavr™ trial.

Mr. Dan O’Brien, CEO, states, “FSI is pleased to announce that a Watersavr™ trial was completed in Southern California during November, December, January, and February. The trial resulted in average water savings of 45%. The full results and details of the trials will be released in April after peer review. The Company hopes that this very successful trial will accelerate the purchase of Watersavr™ in California.”

About Flexible Solutions International

Flexible Solutions International, Inc. (www.flexiblesolutions.com) is an environmental technology company. The Company’s NanoChem Solutions Inc. subsidiary specializes in biodegradable, water-soluble products utilizing thermal polyaspartate (TPA) biopolymers. TPA beta-proteins are manufactured from the common biological amino acid, L-aspartic, and have wide usage, including scale inhibitors, detergent ingredients, water treatment, and crop enhancement. The other divisions manufacture energy and water conservation products for drinking water, agriculture, industrial markets, and swimming pools throughout the world. FSI is the developer and manufacturer of WaterSavr™, the world’s first commercially viable water evaporation suppressant. WaterSavr™ significantly reduces evaporation on reservoirs, lakes, aqueducts, irrigation canals, ponds, and slow moving rivers. Heatsavr™, a “liquid blanket” evaporation retardant for the commercial swimming pool and spa markets, reduces energy costs by 15% to 40%, and can result in reduced indoor pool humidity.

Safe Harbor Provision

The Private Securities Litigation Reform Act of 1995 provides a “Safe Harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statementS with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Flexible Solutions International
206 – 920 Hillside Ave, Victoria, BC V8T 1Z8 CANADA
Jason Bloom
Tel: 250.477.9969
Toll Free: 800.661.3560
Fax: 250.477.9912
Email: info@flexiblesolutions.com

If you have received this news release by mistake, or if you would like to be removed from our update list, please reply to: danielle@flexiblesolutions.com.

To find out more information about Flexible Solutions and our products, please visit www.flexiblesolutions.com.

SOURCE: Flexible Solutions International, Inc.

ReleaseID: 457775

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / For biotech firms, there generally is not much news that will thrills investors. Generally, investors do not expect much from their investment for years as the drug or technology goes through the FDA approval process, which can take 3 years or longer. For these two firms, today was a day for investors to start to celebrate, as one received an important extension from a major pharmaceutical firm, while another makes a breakthrough by breaking from convention.

RDI Initiates
Coverage:

Nektar Therapeutics https://ub.rdinvesting.com/news/?ticker=NKTR

CytomX Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CTMX

The company announced significant positive news from its current drug candidate, NKTR-181. The Phase 3 efficacy study of the drug NKTR-181, which is a first in its class of opioid analgesics indicated the new chemical entity (NCE) that is the first full mu-opioid drug was effective to provide potent pain relief to patients without the high levels of euphoria that a major contributor to drug abuse and addiction that accompany standard opioids. The company’s stock rose $6.61 a share with significantly higher volume to close at $22.21, a decade high. After hours trading showed the stock price continuing to rise. With the granted fast-track designation of NKTR-181, investors are feeling bullish on prospect of improving bottom line, as the company management has indicated in the last conference call about their plan to out-license the drug to an established player and a company with long-term commitment in the pain market. In the ongoing battle against opioid abuse and addiction, the discovery and creation of an opioid pain killer that is safe and non-addictive is a major step in the war against the illegal distribution and sale of prescription drugs.

Access RDI’s Nektar Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=NKTR

One way a small cap biotech firm can get a boost in stock price is by having the confidence of an established pharmaceutical company get behind it. That is exactly what happened to CytomX Therapeutics on Monday, as Bristol-Myers Squibb Company and CytomX announced their expansion of the 2014 strategic collaboration agreement. CytomX is in the process of discovering new therapies for cancer treatment. There are 8 other candidates that will be using CytomX’s proprietary Probody platform. The stock rose $3.71 a share to close at $18.89 per share on Monday. It closed at $15.20 a share on Friday. Earlier this month on March 2nd, the company posted it 2016 full year financials, with a loss of $1.63 a share on a revenue of $15 million for the year 2016, as compared to loss of $4.9 a share on revenue of $7.7 million reported for the year 2015. The company had cash and cash equivalents along with short-term investments of $181.9 million and this the company expects is sufficient enough to sail throughout 2018 to fund its operations without any additional capital infusion.

Access RDI’s CytomX Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CTMX

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and CytomX Therapeutics Inc. (NASDAQ: CTMX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457811

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / Both companies achieved their stability in different ways, but still achieved the same end. That achievement was reflected in their rise in stock prices at Monday’s close. In the biotech sector, financial stability is important for any company to have a chance at seeing their developmental candidates get FDA approval and surge to profitability. For some biotech companies, being able to financially survive through the end of the calendar year is a significant achievement. Sometimes being the only biotech company to pursue a niche treatment has great potential to pay off.

RDI Initiates
Coverage:

Aurinia
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=AUPH

Catalyst
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=CPRX

Aurinia stock made a major move on Monday, closing at $8.78 per share, up from a Friday close of $7.70 per share. The $1.08 advance was credited in large part due to the company’s decision to close $25.645 million common share public offering including fully exercise of its Underwriters’ Option to buy additional common stock for a total gross proceed of $173.1 million. The company is in the process of developing their candidate drug voclosporin, which is targeted for the treatment of lupus nephritis. A number of investment rating firms have raised their “sell” rating to a “hold” in November last year and one company maintaining their “buy” rating in March this year, with majority of firms reiterating ratings as “outperform” in February and March this quarter. The company had about 16 percent of its share in the hand of institutional investors as of December 31, 2016 and numbers of share purchase positions by institutional investors were far higher than number of share sell positions in the quarter. Investors like NEA management and Goldman Sachs have increased their positions in the company in the quarter ending in December.

Access RDI’s Aurinia Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=AUPH

Catalyst was up 12 cents Monday from a daily high of $1.81 a share. After hours trading showed a continued rise in the company’s stock price. Catalyst Pharmaceuticals is a biopharmaceutical company that is currently focused on the development of innovative treatments dealing with rare neuromuscular and neurological diseases. Positive news from FDA Phase 2 trials brought investors and stakeholders up to date with the current progress of its Firdapse(R) (Amifampridine Phosphate) treatment for myasthenia gravis patients. There is no FDA approved therapy for this specific form of MG currently on the market.

Access RDI’s Catalyst Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=CPRX

Our Actionable Research on Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457813